SLEEP · 2023 · 30 citations · 39 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyObesity PreventionSleep MedicineGlucagon-like Peptide-1 Receptor AgonistsIncretin-based TherapiesObesity ManagementObesity PharmacotherapyWeight LossWeight ManagementEnergy Intake ReductionGlucagon Receptor AgonistsGlucagon-like Peptide 1 Receptor AgonismGlucagon-like PeptidesGlycemic Control TargetsObesity TreatmentObstructive Sleep Apnea TherapyObstructive Sleep Apnea Treatment
Obesity is a chronic disease affecting over 670 million adults globally, with multiple complications including obstructive sleep apnea (OSA). Substantial weight loss in patients with obesity-related OSA can reduce or even eliminate OSA as well as reduce sleepiness and improve cardio-metabolic health. Evidence suggests that these improvements exceed those that occur with device-based OSA therapies like continuous positive airway pressure which continue to be the first-line of therapy. Resistance to weight management as a first-line strategy to combat OSA could arise from the complexities in delivering and maintaining adequate weight management, particularly in sleep clinic settings. Recently, incretin-based pharmacotherapies including glucagon-like peptide 1 (GLP-1) receptor agonists alone or combined with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have been developed to target glycemic control in type 2 diabetes. These medications also slow gastric emptying and reduce energy intake. In randomized, placebo-controlled trials of these medications in diabetic and non-diabetic populations with obesity, participants on active medication lost up to 20% of their body weight, with corresponding improvements in blood pressure, lipid levels, physical functioning, and fat mass loss. Their adverse effects are predominantly gastrointestinal-related, mild, and transient. There are trials currently underway within individuals with obesity-related OSA, with a focus on reduction in weight, OSA severity, and cardio-metabolic outcomes. These medications have the potential to substantially disrupt the management of OSA. Pending coming data, we will need to consider pharmacological weight loss as a first-line therapy and how that influences training and management guidelines.
39
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John Wilding, Rachel L. Batterham, Salvatore Calanna et al. · New England Journal of Medicine · 2021 · 4.5K citations · Full text
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad et al. · New England Journal of Medicine · 2022 · 3.2K citations · Full text
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
F. Xavier Pi‐Sunyer, Arne Astrup, Ken Fujioka et al. · New England Journal of Medicine · 2015 · 2.6K citations · Full text